

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

# SAFETY DATA SHEET

FRS-40 SEMI-GLOSS BASE GREY BLUE 2605

### SECTION 1: Identification of the substance/mixture and of the company/ undertaking

### 1.1 Product identifier

Product name SDS code : FRS-40 SEMI-GLOSS BASE GREY BLUE 2605 : 40962605B

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

	Identified uses	
Paint. Professional u	se Industrial use	
	Uses advised against	
All other uses		
Braduat upa	<ul> <li>Solvent here existing for interior use</li> </ul>	

Product use

: Solvent borne coating for interior use.

### 1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

### 1.4 Emergency telephone number

National advisory body/Poi	son	Center
Telephone number	:	145
<u>Supplier</u>		
Telephone number	:	+33 (0)5 34 01 34 01 +33 (0)5 61 60 23 30
Hours of operation	:	

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Product definition : Mixture

#### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H336 STOT RE 2, H373

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	1/19	AkzoNobel

### **SECTION 2: Hazards identification**

See Section 11 for more detailed information on health effects and symptoms.

2

#### 2.2 Label elements

Hazard pictograms



Signal word	:	Warning
Hazard statements	:	Flammable liquid and vapor. Causes skin irritation. Causes serious eye irritation. May cause drowsiness or dizziness. May cause damage to organs through prolonged or repeated exposure.
Precautionary statements		
Prevention	:	Wear protective gloves. Wear eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Do not breathe vapor. Wash hands thoroughly after handling.
Response	:	Get medical advice or attention if you feel unwell. IF INHALED: Call a POISON CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.
Storage	:	Store in a well-ventilated place. Keep container tightly closed. Keep cool.
Disposal	:	Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	:	n-butyl acetate Reaction mass of ethylbenzene and xylene
Supplemental label elements	:	Contains methyl methacrylate. May produce an allergic reaction. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.
Special packaging requirem	en	<u>ts</u>
Containers to be fitted with child-resistant fastenings	:	Not applicable.
Tactile warning of danger	:	Not applicable.
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	None known.



Product/ingredient name	Identifiers	%	Regulation (EC) No. 1272/2008 [CLP]	Туре
p-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥10 - ≤25	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
Reaction mass of ethylbenzene and xylene	REACH #: 01-2119488216-32	≥10 - <20	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
2-methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6	≤10	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
methyl methacrylate	REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6	≤0.3	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335	[1] [2]
cyclohexanone	REACH #: 01-2119453616-35 CAS: 108-94-1 Index: 606-010-00-7	≤0.3	Flam. Liq. 3, H226 Acute Tox. 4, H332	[1] [2]
Hydrocarbons, C11-C14, n- alkanes, isoalkanes, cyclics, <2% aromatics	REACH #: 01-2119456620-43 EC: 926-141-6	≤0.3	Asp. Tox. 1, H304 EUH066	[1]
			See Section 16 for the full text of the H statements declared above.	

### **SECTION 3: Composition/information on ingredients**

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII

[4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

[5] Substance of equivalent concern

[6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.



### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

Eye contact	:	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
Inhalation	:	Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Skin contact	:	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	:	Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	:	No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

#### 4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains methyl methacrylate. May produce an allergic reaction.

#### Over-exposure signs/symptoms

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
	Teuriess



# SECTION 4: First aid measures

Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.

### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	<ul> <li>Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.</li> </ul>
Specific treatments	: No specific treatment.

### **SECTION 5: Firefighting measures**

	5
5.1 Extinguishing media	
Suitable extinguishing media	: Use dry chemical, CO <sub>2</sub> , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.
5.2 Special hazards arising	from the substance or mixture
Hazards from the substance or mixture	: Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion.
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide halogenated compounds metal oxide/oxides
5.3 Advice for firefighters	
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel fro entering. Do not touch or walk through spilled material. Shut off all ignition sou No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.	
For emergency responders	: If specialized clothing is required to de information in Section 8 on suitable an information in "For non-emergency per	d unsuitable materials. See also the
Date of issue/Date of revision	: 2-11-2022	Version : 1.01
Date of previous issue	: 1-10-2022	5/19 AkzoNobel

### **SECTION 6: Accidental release measures**

6.2 Environmental precautions	:	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and materials for	or c	ontainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

### **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Do not breathe vapor or mist. Do not ingest. Avoid contact with eyes, skin and clothing. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

#### Seveso Directive - Reporting thresholds

#### Danger criteria

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	6/19	AkzoNobel

S	SECTION 7: Handling and storage					
		Notification and MAPP threshold	Safety report threshold			
	P5c	5000 tonne	50000 tonne			

#### 7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

### **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

### 8.1 Control parameters

#### **Occupational exposure limits**

Product/ingredient name	Exposure limit values
┏-butyl acetate	SUVA (Switzerland, 1/2020). Notes: not temporary STEL: 960 mg/m <sup>3</sup> 15 minutes. STEL: 200 ppm 15 minutes. TWA: 480 mg/m <sup>3</sup> 8 hours. TWA: 100 ppm 8 hours.
Reaction mass of ethylbenzene and xylene	SUVA (Switzerland, 1/2020). Absorbed through skin. Notes: not temporary STEL: 870 mg/m <sup>3</sup> 15 minutes. STEL: 200 ppm 15 minutes. TWA: 435 mg/m <sup>3</sup> 8 hours. TWA: 100 ppm 8 hours.
2-methoxy-1-methylethyl acetate	SUVA (Switzerland, 1/2018). TWA: 50 ppm 8 hours. TWA: 275 mg/m <sup>3</sup> 8 hours. STEL: 50 ppm 15 minutes. STEL: 275 mg/m <sup>3</sup> 15 minutes.
methyl methacrylate	SUVA (Switzerland, 1/2020). Skin sensitizer. Notes: not temporary STEL: 420 mg/m <sup>3</sup> 15 minutes. STEL: 100 ppm 15 minutes. TWA: 210 mg/m <sup>3</sup> 8 hours. TWA: 50 ppm 8 hours.
cyclohexanone	SUVA (Switzerland, 1/2020). Absorbed through skin. Notes: not temporary STEL: 200 mg/m <sup>3</sup> 15 minutes. STEL: 50 ppm 15 minutes. TWA: 100 mg/m <sup>3</sup> 8 hours. TWA: 25 ppm 8 hours.
procedures atmosphere or of the ventilation protective equilation the following: the assessment limit values and atmospheres - of exposure to (Workplace at	contains ingredients with exposure limits, personal, workplace r biological monitoring may be required to determine the effectiveness on or other control measures and/or the necessity to use respiratory ipment. Reference should be made to monitoring standards, such as European Standard EN 689 (Workplace atmospheres - Guidance for nt of exposure by inhalation to chemical agents for comparison with d measurement strategy) European Standard EN 14042 (Workplace - Guide for the application and use of procedures for the assessment o chemical and biological agents) European Standard EN 482 mospheres - General requirements for the performance of procedures rement of chemical agents) Reference to national guidance
Date of issue/Date of revision : 2-11-2022	Version : 1.01
Date of previous issue: 1-10-2022	7/19 AkzoNobel

### **SECTION 8: Exposure controls/personal protection**

documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

Product/ingredient name	Туре	Exposure	Value	Population	Effects
n-butyl acetate	DNEL	Long term Oral	3.4 mg/kg	General	Systemic
	<b></b>		bw/day	population	
	DNEL	Long term Dermal	3.4 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	7 mg/kg	Workers	Systemic
			bw/day	Conoral	Our terms
	DNEL	Long term	12 mg/m <sup>3</sup>	General	Systemic
	DNEL	Inhalation	19 ma/m <sup>3</sup>	population Workers	Systemia
	DNEL	Long term Inhalation	48 mg/m <sup>3</sup>	workers	Systemic
	DNEL	Long term	102.34 mg/	General	Local
	DINEL	Inhalation	m <sup>3</sup>	population	LUCAI
	DNEL	Long term	480 mg/m <sup>3</sup>	Workers	Local
	DINLL	Inhalation	400 mg/m	WUIKEIS	LUCAI
	DNEL	Short term	859.7 mg/	General	Local
		Inhalation	m <sup>3</sup>	population	
	DNEL	Short term	859.7 mg/	General	Systemic
		Inhalation	m <sup>3</sup>	population	Systemic
	DNEL	Short term	960 mg/m <sup>3</sup>	Workers	Local
		Inhalation	500 mg/m		
	DNEL	Short term	960 mg/m <sup>3</sup>	Workers	Systemic
	DITE	Inhalation	ooo mg/m	Wontono	Cyclonic
Reaction mass of ethylbenzene and	DNEL	Long term Oral	1.6 mg/kg	General	Systemic
xylene			bw/day	population	
Aylono	DNEL	Long term	14.8 mg/m <sup>3</sup>	General	Systemic
		Inhalation		population	
	DNEL	Long term	77 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation			
	DNEL	Long term Dermal	108 mg/kg	General	Systemic
		Donnar	bw/day	population	
	DNEL	Long term Dermal	180 mg/kg	Workers	Systemic
		Donnar	bw/day		
	DNEL	Short term	289 mg/m <sup>3</sup>	Workers	Local
		Inhalation			
	DNEL	Short term	289 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation	Ĭ		
methyl methacrylate	DNEL	Long term Dermal		General	Systemic
		-	bw/day	population	-
	DNEL	Long term Dermal	13.67 mg/	Workers	Systemic
			kg bw/day		
	DNEL	Long term	74.3 mg/m <sup>3</sup>	General	Systemic
		Inhalation		population	
	DNEL	Long term	104 mg/m <sup>3</sup>	General	Local
	_	Inhalation		population	
	DNEL	Long term	208 mg/m <sup>3</sup>	Workers	Local
		Inhalation			
	DNEL	Long term	208 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation			
cyclohexanone	DNEL	Short term Dermal	1 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	1 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Short term Oral	1.5 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Oral	1.5 mg/kg	General	Systemic
			bw/day	population	
- of isour /Data of multiplice	1	<u> </u>	Variation	. 1 01	1
	1-2022			: 1.01	AkzoNo
e of previous issue :1-1	0-2022		8/19		ANZUNU

•		ersonal prote			
	DNEL	Short term Dermal	4 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Dermal	4 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	10 mg/m <sup>3</sup>	General population	Systemic
	DNEL	Long term Inhalation	20 mg/m³	General population	Local
	DNEL	Short term Inhalation	20 mg/m³	General population	Systemic
	DNEL	Short term Inhalation	40 mg/m³	General population	Local
	DNEL	Long term Inhalation	40 mg/m³	Workers	Local
	DNEL	Long term Inhalation	40 mg/m³	Workers	Systemic
	DNEL	Short term Inhalation	80 mg/m³	Workers	Local
	DNEL	Short term Inhalation	80 mg/m³	Workers	Systemic

### **PNECs**

No PNECs available.

8.2 Exposure controls			
Appropriate engineering controls	ventilation or other contaminants below controls also need	uate ventilation. Use process enclosu engineering controls to keep worker e v any recommended or statutory limits to keep gas, vapor or dust concentrati se explosion-proof ventilation equipme	xposure to airborne .  The engineering ons below any lower
Individual protection meas	sures		
Hygiene measures	before eating, smo Appropriate technic Wash contaminate	rms and face thoroughly after handling king and using the lavatory and at the jues should be used to remove potenti d clothing before reusing. Ensure that close to the workstation location.	end of the working period. ially contaminated clothing.
Eye/face protection	assessment indicat gases or dusts. If o	nplying with an approved standard sho es this is necessary to avoid exposure contact is possible, the following protect nent indicates a higher degree of protect	e to liquid splashes, mists, ction should be worn,
Skin protection			
Hand protection	be worn at all times this is necessary. ( check during use th should be noted tha different for differer	impervious gloves complying with an when handling chemical products if a Considering the parameters specified I hat the gloves are still retaining their pr at the time to breakthrough for any glovent glove manufacturers. In the case of the protection time of the gloves can	risk assessment indicates by the glove manufacturer, otective properties. It ve material may be mixtures, consisting of
	protection class of recommended. Re When only brief co (breakthrough time Recommended glo	frequently repeated contact may occu 6 (breakthrough time >480 minutes ac commended gloves: Viton $\circledast$ or Nitrile, ntact is expected, a glove with protecti >30 minutes according to EN374) is r ves: Nitrile, thickness $\ge$ 0.12 mm. eplaced regularly and if there is any sig	cording to EN374) is , thickness ≥ 0.38 mm. on class of 2 or higher ecommended.
Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	9/19	AkzoNobel

### **SECTION 8: Exposure controls/personal protection**

		The performance or effectiveness of the glove may be reduced by physical/ chemical damage and poor maintenance.
		The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.
Body protection	:	Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	:	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	:	Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	:	Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

# **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

<u>Appearance</u>		
Physical state	:	Liquid.
Color	:	Gray.
Odor	:	Characteristic.
Odor threshold	:	Not available.
рН	:	Not available.
Melting point/freezing point	:	Not available.
Initial boiling point and boiling range	:	Not available.
Flash point	:	Closed cup: 28°C
Evaporation rate	:	Not available.
Flammability (solid, gas)	:	Not available.
Upper/lower flammability or explosive limits	:	Not available.
Vapor pressure	:	Not available.
Vapor density	:	Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Weighted average: 4.03 (Air = 1)
Density	:	1.292 g/cm³
Solubility(ies)	:	Insoluble in the following materials: cold water.
Partition coefficient: n-octanol/ water	:	Not available.
Auto-ignition temperature	:	Not available.
Decomposition temperature	:	Not available.
Viscosity	:	Kinematic (room temperature): 7.74 cm²/s Kinematic (40°C): 1.01 cm²/s

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	10/19	AkzoNobel

# **SECTION 10: Stability and reactivity**

10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.
10.5 Incompatible materials	: Reactive or incompatible with the following materials: oxidizing materials
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

# **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

### Acute toxicity

prbutyl acetate LC50 Inhalation Gas. LC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation Vapor LD50 Dermal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LC50 Inhalation Gas. ethylbenzene and xylene methyl methacrylate LC50 Inhalation Vapor tLC50 Inhalation Vapor LC50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50	Product/ingredient name	Result	Species	Dose	Exposure
LC50 Inhalation Vapor     Mouse     6 g/m³     2 hours       LD50 Dermal     Rabbit     >17600 mg/kg     -       LD50 Oral     Guinea pig     4700 mg/kg     -       LD50 Oral     Mouse     6 g/kg     -       LD50 Oral     Mouse     6 g/kg     -       LD50 Oral     Rabbit     3200 mg/kg     -       LD50 Oral     Rabbit     3200 mg/kg     -       LD50 Oral     Rat     10768 mg/kg     -       LD50 Oral     Rat     10768 mg/kg     -       LD50 Oral     Rat     5000 ppm     4 hours       Ethylbenzene and xylene     LC50 Inhalation Vapor     Mouse     18500 mg/m³     2 hours       LD50 Dermal     Ratbit     >5 g/kg     -     -       LD50 Intraperitoneal     Guinea pig     1890 mg/kg     -       LD50 Intraperitoneal     Mouse     3625 mg/kg     -       LD50 Varal     Guinea pig     5954 mg/kg     -       LD50 Subcutaneous     Guinea pig     5954 mg/kg     -       LD50 Intraperitoneal     Rat     7088 mg/kg     -       LD50 Subcutaneous     Rat     7088 mg/kg     -       LD50 Subcutaneous     Rat     7088 mg/kg     -       LD50 Intraperitoneal     Guinea pig	p-butyl acetate	LC50 Inhalation Gas.	Rat	390 ppm	4 hours
LD50 Dermal LD50 IntraperitonealRabbit>17600 mg/kg-LD50 Intraperitoneal LD50 OralMouse1230 mg/kg-LD50 Oral LD50 OralMouse6 g/kg-LD50 Oral LD50 OralRabbit3200 mg/kg-LD50 Oral LD50 OralRat10768 mg/kg-LD50 Oral LD50 OralRat10768 mg/kg-LC50 Inhalation Gas.Rat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 IntraperitonealMouse18500 mg/m³2 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig1900 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse945 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 SubcutaneousMouse3625 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7872 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1230 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg- </td <td rowspan="2">·</td> <td>LC50 Inhalation Vapor</td> <td>Mouse</td> <td></td> <td>2 hours</td>	·	LC50 Inhalation Vapor	Mouse		2 hours
LD50 Intraperitoneal LD50 OralMouse Guinea pig Guinea pig 4700 mg/kg-Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat10768 mg/kg-LC50 Inhalation Gas.Rat10768 mg/kgLC50 Inhalation Gas.Rat78000 mg/m³2 hoursLC50 Inhalation Vapor LC50 Inhalation VaporRat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 DermalGuinea pig Guinea pig1890 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig945 mg/kg-LD50 Oral LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralGuinea pig Guinea pig5954 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Subcutaneous LD50 SubcutaneousGuinea pig Guinea pig5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7808 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 IntraperitonealGuinea pig Guinea pig930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg </td <td>LD50 Dermal</td> <td>Rabbit</td> <td></td> <td>-</td>		LD50 Dermal	Rabbit		-
LD50 OralGuinea pig Mouse4700 mg/kg G /kg-LD50 OralLD50 OralRabbit3200 mg/kg-LD50 OralRat10768 mg/kg-LD50 OralRat10768 mg/kg-LD50 OralRat5000 ppm4 hoursethylbenzene and xyleneLC50 Inhalation VaporMouse18500 mg/m³2 hoursLC50 Inhalation VaporRat78000 mg/m³4 hoursLC50 Inhalation VaporRat78000 mg/m³4 hoursLD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRatit1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitone		LD50 Intraperitoneal	Mouse		-
LD50 Oral LD50 OralMouse6 g/kg-Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat10768 mg/kg-LC50 Inhalation Vapor LD50 DermalMouse18500 mg/m³2 hoursLC50 Inhalation Vapor LD50 DermalRat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 IntraperitonealRat>5 g/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig1890 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 SubcutaneousMouse5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat </td <td></td> <td></td> <td>Guinea pig</td> <td>4700 mg/kg</td> <td>-</td>			Guinea pig	4700 mg/kg	-
LD50 Oral LD50 Oral LD50 Oral ethylbenzene and xylene methyl methacrylateLD50 Oral LC50 Inhalation Gas.Rat10768 mg/kg 5000 ppm-LC50 Inhalation Vapor LC50 Inhalation VaporMouse18500 mg/m³2 hoursLC50 Inhalation Vapor LD50 DermalRat78000 mg/m³4 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig5954 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 SubcutaneousRat7872 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig S954 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intrap		LD50 Oral			-
Reaction mass of ethylbenzene and xylene methyl methacrylateLD50 Oral LC50 Inhalation Gas.Rat10768 mg/kg s000 ppm4 hoursLC50 Inhalation Gas.Rat5000 ppm4 hoursLC50 Inhalation Vapor LD50 IntraperitonealMouse18500 mg/m³2 hoursLD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealRat7088 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1		LD50 Oral	Rabbit		-
Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat5000 ppm4 hoursLC50 Inhalation Vapor LD50 Intraperitoneal 		LD50 Oral	Rat	10768 mg/kg	-
methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LD50 DermalMouse18500 mg/m³2 hoursLD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7870 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealRabbit1 mL/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperi		LC50 Inhalation Gas.	Rat		4 hours
LC50Inhalation VaporRat78000 mg/m³4 hoursLD50DermalRabbit>5 g/kg-LD50IntraperitonealGuinea pig1890 mg/kg-LD50IntraperitonealMouse945 mg/kg-LD50IntraperitonealRat1328 mg/kg-LD50OralGuinea pig5954 mg/kg-LD50OralGuinea pig5954 mg/kg-LD50OralMouse3625 mg/kg-LD50OralRat7872 mg/kg-LD50OralRat7872 mg/kg-LD50SubcutaneousMouse5954 mg/kg-LD50SubcutaneousMouse5954 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50IntraperitonealGuinea pig930 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealRabbit1540 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130		LC50 Inhalation Vapor	Mouse	18500 ma/m <sup>3</sup>	2 hours
LD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 DermalRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-<	, ,		Rat		4 hours
LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg-					-
LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 DermalRat7088 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1130 mg/kg-LD50 Oral<			Guinea pig		-
LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat100 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 Oral Mouse 3625 mg/kg - LD50 Oral Rabbit 8700 mg/kg - LD50 Oral Rat 7872 mg/kg - LD50 Subcutaneous Guinea pig 5954 mg/kg - LD50 Subcutaneous Mouse 5954 mg/kg - LD50 Subcutaneous Rat 7088 mg/kg - LD50 Subcutaneous Rat 8000 ppm 4 hours LD50 Dermal Rabbit 1 mL/kg - LD50 Dermal Guinea pig 930 mg/kg - LD50 Intraperitoneal Guinea pig 930 mg/kg - LD50 Intraperitoneal Mouse 1230 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rat 1130 mg/kg -			Guinea pig		-
LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 SubcutaneousRat7088 mg/kg-LC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1240 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
cyclohexanoneLC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Rat		-
LD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1400 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-	cyclohexanone	LC50 Inhalation Gas.	Rat		4 hours
LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1400 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-		LD50 Dermal	Rabbit		-
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-		LD50 Intraperitoneal	Guinea pig		-
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Mouse		-
LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Rabbit		-
LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Rabbit		-
LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Rat		-
LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-				1130 mg/kg	-
LD50 Oral Rat 1800 mg/kg - LD50 Oral Rat 1620 uL/kg -			Mouse		-
LD50 Oral Rat 1620 uL/kg -			Rat		-
					-
					-
e of issue/Date of revision : 2-11-2022 Version : 1.01			•	·	•

11/19



### **SECTION 11: Toxicological information**

#### : Not available. **Conclusion/Summary**

Product/ingredient name	Result	Species	Score	Exposure	Observation
p-butyl acetate	Eyes - Moderate irritant	Rabbit	_	100 mg	_
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
Reaction mass of ethylbenzene and xylene	Eyes - Mild irritant	Rabbit	-	87 mg	-
	Eyes - Severe irritant	Rabbit	-	24 hours 5 mg	-
	Skin - Mild irritant	Rat	-	8 hours 60 UI	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
	Skin - Moderate irritant	Rabbit	-	100 %	-
cyclohexanone	Eyes - Severe irritant	Rabbit	-	24 hours 250	-
				ug	
	Eyes - Severe irritant	Rabbit	-	20 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
Conclusion/Summary	: Not available.				
<u>Sensitization</u>					
Conclusion/Summary	: Not available.				
Mutagenicity					
Conclusion/Summary	: Not available.				
Carcinogenicity					
Conclusion/Summary	: Not available.				
Reproductive toxicity					
Conclusion/Summary	: Not available.				
Teratogenicity					
Conclusion/Summary	: Not available.				

### Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
<b>n</b> -butyl acetate Reaction mass of ethylbenzene and xylene	Category 3 Category 3	-	Narcotic effects Respiratory tract irritation
2-methoxy-1-methylethyl acetate methyl methacrylate	Category 3 Category 3	-	Narcotic effects Respiratory tract irritation

### Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Reaction mass of ethylbenzene and xylene	Category 2	-	-

### Aspiration hazard

Product/ingredient name	Result
Reaction mass of ethylbenzene and xylene Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1

#### Information on the likely : Not available. routes of exposure



### **SECTION 11: Toxicological information**

SECTION 11: Toxico	logical information
Potential acute health effects	<u>s</u>
Eye contact	: Causes serious eye irritation.
Inhalation	: Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.
Skin contact	: Causes skin irritation.
Ingestion	: Can cause central nervous system (CNS) depression.
Symptoms related to the phy	vsical, chemical and toxicological characteristics
Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
Delayed and immediate effect	cts and also chronic effects from short and long term exposure
<u>Short term exposure</u>	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health eff	ects
Not available.	
Conclusion/Summary	: Not available.
General	: May cause damage to organs through prolonged or repeated exposure.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.
Other information	: Not available.

### **SECTION 12: Ecological information**

### 12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment, but contains substance(s) hazardous to the environment. See section 3 for details.

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	13/19	AkzoNobel

# **SECTION 12: Ecological information**

Product/ingredient name	Result	Species	Exposure
n-butyl acetate	Acute LC50 32 mg/l Marine water	Crustaceans - Artemia salina	48 hours
	Acute LC50 100000 µg/l Fresh water	Fish - Lepomis macrochirus	96 hours
	Acute LC50 18000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 185000 µg/l Marine water	Fish - Menidia beryllina	96 hours
	Acute LC50 62000 µg/l Fresh water	Fish - Danio rerio	96 hours
Reaction mass of ethylbenzene and xylene	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours
methyl methacrylate	Acute LC50 191000 µg/l Fresh water	Fish - Lepomis macrochirus - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Acute LC50 159100 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 160200 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 150000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
	Acute LC50 130000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
cyclohexanone	Acute EC50 32.9 mg/l Fresh water	Algae - Chlamydomonas reinhardtii - Exponential growth phase	72 hours
	Acute LC50 630000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 527000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 732000 µg/l Fresh water	Fish - Pimephales promelas	96 hours

Conclusion/Summary

: Not available.

### 12.2 Persistence and degradability

**Conclusion/Summary** : Not available.

#### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
-butyl acetate	2.3	-	low
Reaction mass of ethylbenzene and xylene	3.12	8.1 to 25.9	low
2-methoxy-1-methylethyl acetate	1.2	-	low
methyl methacrylate cyclohexanone	1.38 0.86	-	low low

#### 12.4 Mobility in soil

Soil/water partition coefficient (Koc)	: Not available.
Mobility	: Not available.

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

**12.6 Other adverse effects** : No known significant effects or critical hazards.



### **SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
Disposal considerations	<ul> <li>Do not allow to enter drains or watercourses.</li> <li>Dispose of according to all federal, state and local applicable regulations.</li> <li>If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned.</li> <li>For further information, contact your local waste authority.</li> </ul>

#### European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Waste code	Waste designation	
EWC 08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances	
Packaging		
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.	
Disposal considerations	<ul> <li>Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.</li> </ul>	
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.	

# **SECTION 14: Transport information**

	ADR/RID	IMDG		ΙΑΤΑ
14.1 UN number	UN1263	UN1263	UN1263	
14.2 UN proper shipping name	PAINT	PAINT	PAINT	
14.3 Transport hazard class(es)	3	3	3	
14.4 Packing group	111			
Date of issue/Date of rev	rision : 2-11-2022	Versio	on :1.01	
Date of previous issue	: 1-10-2022	15/19		AkzoNobe

SECTION 14: Transport information							
14.5 Environmental hazards	No.			No.		No.	
Additional informat	tion						_
ADR/RID		pa	-	50 L according to	•	id is not subject to regulation in	
IMDG		<u>Vis</u>	cous liquid exc	<u>lules</u> F-E, _S-E_ <u>ception</u> This clas 50 L according to	•	id is not subject to regulation in	
14.6 Special precautions for user		: <b>Transport within user's premises:</b> always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.					
14.7 Transport in bu according to IMO instruments	ılk	: No	t applicable.				
SECTION 15: Regulatory information							
15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)							

### Annex XIV - List of substances subject to authorization

Annex XIV	-		
None of the components a	re listed.		
Substances of very high			
None of the components a	re listed.		
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	: Not ap	plicable.	
<u>Other EU regulations</u>			
VOC		ovisions of Directive 2004/42/EC on VOC apply to th t label and/or technical data sheet for further information	
VOC for Ready-for-Use Mixture	: Not app	plicable.	
Industrial emissions (integrated pollution prevention and control) - Air	: Not list	ted	
Industrial emissions (integrated pollution prevention and control) - Water	: Not list	ted	
Ozone depleting substanc	es (1005/2	<u>:009/EU)</u>	
Not listed.			
Prior Informed Consent (P Not listed.	<u>IC) (649/20</u>	<u>012/EU)</u>	
Seveso Directive			
ate of issue/Date of revision	: 2-11-2	2022 Version : 1.01	

Date of previous issue	: 1-10-2022	16/19



٦

SECTION 15: Regulatory information					
This product is controlled under the Seveso Directive.					
Danger criteria					
Category					
P5c					
National regulations					
Industrial use	: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.				
VOC content	: VOC (w/w): 40.7%				
International regulations					
	ntion List Schedules I, II & III Chemicals				
Not listed.					
Montreal Protocol					
Not listed.					
Stockholm Convention of Not listed.	n Persistent Organic Pollutants				
Rotterdam Convention or Not listed.	n Prior Informed Consent (PIC)				
UNECE Aarhus Protocol ( Not listed.	on POPs and Heavy Metals				
Inventory list					
Europe	: Not determined.				
15.2 Chemical Safety Assessment	: No Chemical Safety Assessment has been carried out.				
<b>SECTION 16: Other</b>	r information				
Indicates information that	Indicates information that has changed from previously issued version.				
Abbreviations and acronyms	<ul> <li>ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number Soco = Socration Crown</li> </ul>				

SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Flam. Liq. 3, H226	On basis of test data
Skin Irrit. 2, H315	Calculation method
Eye Irrit. 2, H319	Calculation method
STOT SE 3, H336	Calculation method
STOT RE 2, H373	Calculation method

### Full text of abbreviated H statements

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	5. S. S
Date of previous issue	: 1-10-2022	17/19	AkzoNobel

SECTION 16: Other information			
<b>H</b> 225		Highly flammable liquid and vapor.	
H226		Flammable liquid and vapor.	
H304		May be fatal if swallowed and enters airways.	
H312		Harmful in contact with skin.	
H315		Causes skin irritation.	
H317		May cause an allergic skin reaction.	
H319		Causes serious eye irritation.	
H332		Harmful if inhaled.	
H335		May cause respiratory irritation.	
H336		May cause drowsiness or dizziness.	
H373		May cause damage to organs through prolonged or repeated	
		exposure.	
H412		Harmful to aquatic life with long lasting effects.	
EUH066		Repeated exposure may cause skin dryness or cracking.	
Full text of classifications	[CLP/GHS]		
Acute Tox. 4		ACUTE TOXICITY - Category 4	
Aquatic Chronic 3		AQUATIC HAZARD (LONG-TERM) - Category 3	
Asp. Tox. 1		ASPIRATION HAZARD - Category 1	
Eye Irrit. 2		SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2	
Flam. Liq. 2		FLAMMABLE LIQUIDS - Category 2	
Flam. Liq. 3		FLAMMABLE LIQUIDS - Category 3	
Skin Irrit. 2		SKIN CORROSION/IRRITATION - Category 2	
Skin Sens. 1		SKIN SENSITIZATION - Category 1	
STOT RE 2		SPECIFIC TARGET ORGAN TOXICITY (REPEATED	
		EXPOSURE) - Category 2	
STOT SE 3		SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) -	
		Category 3	
Date of printing	: 2 November 20	22	
Date of issue/ Date of revision	: 2 November 20	22	
Date of previous issue	: 1 October 2022		
Version	: 1.01		
Unique ID	:		
Notico to reader			

### Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.



